Neurocrine Biosciences | NBIX - Eigenkapital Und Reserven





Eigenkapital Und Reserven Veränderung Datum
AbbVie USD -3.27B 628M 2025-12
Acadia Pharmaceuticals USD 917.27M 94.89M 2025-09
Agios Pharmaceuticals USD 1.19B 91.22M 2025-12
ALKERMES USD 1.82B 85.86M 2025-12
Alnylam Pharmaceuticals USD 789.18M 555.28M 2025-12
Amgen USD 8.66B 961M 2025-12
Biogen USD 18.21B 573.5M 2025-09
BioMarin Pharmaceutical USD 6.09B 30.29M 2025-12
Cytokinetics USD -659.62M 138.5M 2025-12
Enanta Pharmaceuticals USD 126.59M 61.87M 2025-12
Exelixis USD 2.16B 619K 2025-12
Gilead Sciences USD 22.62B 1.16B 2025-12
Halozyme Therapeutics USD 48.81M 455.1M 2025-12
Incyte USD 5.17B 516.28M 2025-12
Ionis Pharmaceuticals USD 617.97M 13.76M 2025-09
Nektar Therapeutics USD 89.83M 4.75M 2025-12
Neurocrine Biosciences USD 3.25B 249.5M 2025-12
Pfizer USD 92.8B 4.11B 2025-09
Prothena USD 280.47M 14.51M 2025-12
Regeneron Pharmaceuticals USD 31.26B 299.1M 2025-12
Repligen USD 2.11B 1.66B 2025-12
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
Sarepta Therapeutics USD 1.14B 179.5M 2025-12
Teva Pharmaceutical Industries USD 7.91B 664M 2025-12
Ultragenyx Pharmaceutical USD 9.16M 142.13M 2025-09
Vertex Pharmaceuticals USD 18.67B 1.35B 2025-12
Xoma USD 87.94M 15.5M 2025-09